CAPACITIES OF TOPICAL ANTIFUNGAL AGENTS TO TREAT GENITAL CANDIDIASIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study current ideas on the specific features of vulvovaginal candidiasis (VVC) and ways of its correction according to the data of Russian and foreign investigations. Material and methods. Information was sought in the international and Russian databases, by using key words, such as genital candidiasis, antimycotic therapy, and sertaconazole. Twenty sources reflecting the state of the problem are selected. Results. The paper presents literature data on the clinical course of VVC and current procedures for its diagnosis. It also gives the results of multicenter European and Russian investigations suggesting the clinical efficacy of sertaconazole. Conclusion. To treat patients with VVC, it is necessary to use broad-spectrum antimycotics against its uncomplicated course. Comparative analysis of different antimycotics has shown the benefit of sertaconazole - its clinical efficacy during short-term treatment.

Full Text

Restricted Access

About the authors

Svetlana Ivanovna Rogovskaya

Russian State Academy of Postgraduate Education, Ministry of Health of Russia

Email: srogovskaya@mail.ru
MD, professor of the Department of Obstetrics and Gynecology, Pediatrics Faculty Moscow 121552, Barrikadnaya str. 2/1, Russia

Tamara Nikolaevna Bebneva

Peoples' Friendship University of Russia, Ministry of Education of Russia

Email: bebn@mail.ru
PhD, assistant professor of obstetrics, gynecology and reproductive medicine Moscow 117198, Miklukho-Maclaya, str. 6, Russia

L. V Tkachenko

Volgograd State Medical University

MD, professor, head of the Department of Obstetrics and Gynecology Volgograd 400066, Pavshih boitsov sq. 1, Russia

References

  1. Байрамова Г.Р., Муравьева В.В., Донников А.Е., Бурменская О.В., Ворошилина Е.С., Тумбинская Л.В. Оценка эффективности комплексной терапии больных с хроническим рецидивирующим вульвовагинальным кандидозом. Российский вестник акушера-гинеколога. 2011; 11(2): 86-9.
  2. Мирзабалаева А.К. Кандидоз гениталий в акушерско-гинекологической практике. StatusPraesens. 2011; 1(4): 56-61.
  3. Липова E.B. Урогенитальный кандидоз женщин: проблемы и пути решения. Гинекология. 2008; 10(5): 35-8.
  4. Профилактика, диагностика и лечение инфекций, передаваемых половым путем. Руководство для дерматовенерологов, акушеров- гинекологов, урологов и семейных врачей. М.: Институт Здоровья Семьи; 2008.
  5. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin. Microbiol. Rev. 2010; 23(2): 253-73.
  6. Кубанова A.A., ред. Ведение больных с инфекциями, передаваемыми половым путем, и урогенитальными инфекциями. Клинические рекомендации. М.: Деловой экспресс; 2012. 112с.
  7. Workowski K.A., Berman S.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 2010; 59(RR-12): 1-110. Available at: http://www.cdc.gov/std/treat- ment/2010/vaginaldischarge
  8. Filler S.G. Insights from human studies into the host defense against candidiasis. Cytokine. 2012; 58(1): 129-32.
  9. Patel D.A., Gillespie B., Sobel J.D., Leaman D., Nyirjesy P, Weitz M.V., Foxman B. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am. J. Obstet. Gynecol. 2004; 190(3): 644-53.
  10. Соловьева A.В., ҒІлаксина Н.Д., Сильвестрова FA. Вульвовагинальный кандидоз: как избежать рецидивов. Клиническая лекция. Радзинский В.Е., ред. М.: StatusPraesens; 2013. 16с.
  11. Киселева E.IJ. Иммунитет при микозах, ч. 1: Роль врожденного иммунитета. Пособие для врачей. СПб.;2009.24с.
  12. Andriole V.T. Current and future antifungal therapy: new targets for antifungal therapy. Int. J. Antimicrob. Agents. 2000; 16(3): 317-21.
  13. Evseenko I.A., Saluk Y.V., Sidelnikov E.L. Causative agents of dermatophy- toses and candidoses in Minsk, Belarus. JEADV J. Eur. Acad. Dermatol. Venereol. 2004; 18 (Suppl.l): 54-5.
  14. KlepserM.E. Antifungal resistance among Candida species. Pharmacotherapy. 2001; 21(8, Pt2): 124S-132S.
  15. Esim Buyukbayrak E., Kars B., Karsidag A.Y., Karadeniz B.I., Kaymaz O., Gencer S. et al. Diagnosis of vulvovaginitis: comparison of clinical and microbiological diagnosis. Arch. Gynecol. Obstet. 2010; 282(5): 515-59.
  16. Hkit M., Guzel A.B. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit. Rev. Microbiol. 2011; 37(3): 250-61.
  17. Buchta V, Spacek J. Pitfalls of the current laboratory diagnosis and treatment of vulvovaginal can-didiasis. Klin. Mikrobiol. Infekc. Lek. 2011; 17(5): 158-63.
  18. Mendling W., Brasch J. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012; 55(Suppl.3): 1-13.
  19. Carrillo-Munoz A.J., Tur-Tur C., Giusiano G., Marcos-Arias C., Eraso E., Jauregizar N., Quindds G. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Exp. Rev. Anti Infect. Ther. 2013; 11(4): 347-58.
  20. Wang P.H., Chao H.T., Chen C.L., Yuan C.C. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J. Chin. Med. Assoc. 2006; 69(6): 259-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies